Conavi Medical (TSXV:CNVI) has announced that the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC) has published a peer-reviewed article detailing recent advances in hybrid...
PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines...
Klotho Neurosciences (NASDAQ:KLTO) has appointed Makoto Kuro-o, MD, Ph.D., to its scientific advisory board. Dr. Kuro-o, a pioneer in the discovery of the anti-aging Klotho (s-KL) gene, will support Klotho’s mission to...
Olema Oncology (NASDAQ:OLMA) has announced results from three preclinical studies demonstrating the robust anti-tumor activity of OP-3136 as a single agent and in combination with palazestrant. The results will be...
Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...
SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential...
Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...
Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...
PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...
Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...
Capricor Therapeutics (NASDAQ:CAPR) has priced a public offering of 4,412,000 common shares at a price of $17.00 per share. Capricor also granted underwriters a 30-day option to purchase up to an additional 661,800...
Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...